NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Lamivudine for Chronic Hepatitis B
Phase 2
Completed
- Conditions
- Chronic Hepatitis BChronic Hepatitis DGlomerulonephritisPolyarteritis Nodosa
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 60
- Registration Number
- NCT00001457
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection
Phase 1
Completed
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infection
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00001386
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer
Completed
- Conditions
- Breast NeoplasmHereditary Neoplastic Syndrome
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00001496
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
Phase 2
Completed
- Conditions
- AcromegalyPituitary Neoplasm
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 5
- Registration Number
- NCT00001860
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
Phase 2
Completed
- Conditions
- Prostatic Neoplasm
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT00001266
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
Completed
- Conditions
- AlcoholismHIV InfectionHomosexualityKaposi's Sarcoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2000
- Registration Number
- NCT00001294
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Tissue Acquisition for Molecular Diagnostics
Completed
- Conditions
- Neoplasm
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00001580
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients
Phase 1
Completed
- Conditions
- Breast CancerBreast Neoplasm
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00001504
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Oxaliplatin in Cancer Patients With Impaired Kidney Function
Phase 1
Completed
- Conditions
- Kidney DiseaseNeoplasmNeoplasm Metastasis
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00001835
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma
Phase 2
Completed
- Conditions
- Ewing's SarcomaNeuroblastomaRhabdomyosarcoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 90
- Registration Number
- NCT00001335
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath